A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Trial Profile

A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Imalumab (Primary) ; Fluorouracil; Panitumumab
  • Indications Colon cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Baxalta; Baxter Corporation; Shire
  • Most Recent Events

    • 02 Jun 2017 Status changed from active, no longer recruiting to discontinued.
    • 02 Mar 2017 This study has been completed in Spain as Eudra(end date- 2017-02-18)
    • 15 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top